Fulcrum Therapeutics (FULC) Accounts Payables (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accounts Payables data on file, last reported at $2.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.4 million, up 62.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 62.57% YoY), and the FY2025 annual result was $1.6 million, up 36.77% from the prior year.
• Accounts Payables climbed to $2.4 million in Q1 2026 per FULC's latest filing, from $1.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $6.0 million in Q1 2022 and troughed at $1.2 million in Q4 2024.
• A 5-year average of $3.2 million and a median of $3.6 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables sank 60.93% in 2025, then jumped 62.57% in 2026.
• A 5-year view of Accounts Payables shows it stood at $3.6 million in 2022, then dropped by 24.22% to $2.8 million in 2023, then plunged by 57.78% to $1.2 million in 2024, then jumped by 36.77% to $1.6 million in 2025, then surged by 53.89% to $2.4 million in 2026.
• Business Quant data shows FULC's Accounts Payables at $2.4 million in Q1 2026, $1.6 million in Q4 2025, and $2.9 million in Q3 2025.